Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• PD (Progressive Disease)-1 inhibitors combined with chemotherapy significantly improved overall survival (OS) from 11.3 months to 15.6 months, with Tislelizumab achieving notable OS benefits in patients with a combined positive score (CPS) of ≥10 (HR (Hazard Ratio): 0.71).
• Camrelizumab provided the best progression-free survival (PFS) benefits (HR: 0.69), while pembrolizumab demonstrated the most effective OS benefits (HR: 0.55).
• In patients with high PD-L1 expression (CPS ≥10, TPS ≥1%), sintilimab and camrelizumab showed superior OS and PFS outcomes compared to other PD-1 inhibitors.
• PD-1 inhibitors, including tislelizumab, were associated with increased risks of immune-related adverse events such as hypothyroidism, hyperthyroidism, thyroiditis, diabetes mellitus, and adrenal insufficiency in various tumor types, including non-small cell lung cancer and melanoma.
• Nivolumab demonstrated a lower incidence of treatment-related adverse events and grade 3-5 adverse events compared to other PD-1 inhibitors, with fewer significant safety concerns noted.
• The reviewed studies focus on specific population types such as patients with advanced esophageal squamous cell carcinoma (ESCC), advanced or metastatic ESCC in the context of the Chinese healthcare system, non-small cell lung cancer, and melanoma. Clinically relevant findings indicate that subgroups with high PD-L1 expression (CPS ≥10 and TPS ≥1%) benefit more from certain PD-1 inhibitors like sintilimab in terms of overall survival. Additionally, patients with non-small cell lung cancer and melanoma experience higher risks of specific endocrinopathies, such as thyroiditis and adrenal insufficiency.